Linezolid for the treatment of diabetic foot infections

Skinner, Stuart; Embil, John M.

doi:10.2217/14750708.4.1.41

Cited by 2 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies suggested that individuals with a reduced or completely absent antiplatelet response to ASA might experience higher risks of vascular events. The cardiovascular risks were found to be higher in patients with ASA resistance when compared to those who had sufficient responses to ASA [1,2,3,4]. There are some data suggesting an association between severity and frequency of acute vascular events and poor platelet response after ASA in patients with coronary artery disease [5].…”

Section: Introductionmentioning

confidence: 99%

Plasma Triglycerides as Predictors of Platelet Responsiveness to Aspirin in Patients after First Ischemic Stroke

Karepov¹,

Tolpina²,

Kuliczkowski

et al. 2008

Cerebrovasc Dis

View full text Add to dashboard Cite

Background: Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%. Platelet function monitoring in ASA users suggests that some individuals exhibit a reduced or even absent antiplatelet response after ASA. This phenomenon, also known as ‘resistance’, is prevalent in stroke survivors. We sought to evaluate the blood lipid profile in poststroke ASA users dependent on their antiplatelet response to ASA. Methods: Ninety-six consecutive ASA users after first-ever ischemic stroke confirmed by imaging were prospectively enrolled. The platelet function analyzer (PFA-100, Dade Behring, USA) was utilized to assess the response after ASA. The lipid profile (total cholesterol, high-density lipoprotein, low-density lipoprotein and triglycerides) was measured using the Cardiochek instrument (Polymer Technology, USA) from the autologuos blood samples. Results: The poststroke duration was 3–26 months, and all patients were treated with ASA for at least 3 months. The allowed daily ASA doses were from 75 up to 325 mg, with a mean of 158 mg. The mean age of the patients was 71 years, almost 60% were women, and over 85% of the patients were treated with statins. Thirty-seven patients were identified as low ASA responders, while 59 patients exhibited an adequate response. There were no differences between ASA responders and nonresponders with regard to demographics, clinical characteristics, risk factors and concomitant medications. The lipid profile biomarkers were similar between groups with the exception of triglycerides, which were significantly increased in the patients with ASA resistance, compared with ASA responders. Conclusion: The fact that hypertriglyceridemia affects platelet response to ASA has potential practical implications in light of growing evidence that ASA may exert antiplatelet properties beyond the cyclooxygenase pathway. The mechanism of such an association is unclear but may be related to the diminished platelet membrane fluidity and inability of ASA to downregulate such ‘strong’ protected platelets.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma Triglycerides as Predictors of Platelet Responsiveness to Aspirin in Patients after First Ischemic Stroke

Karepov¹,

Tolpina²,

Kuliczkowski

et al. 2008

Cerebrovasc Dis

View full text Add to dashboard Cite

show abstract

New oxazolidinones

Prasad¹

2007

Current Opinion in Microbiology

View full text Add to dashboard Cite

Due to the emergence of resistance to known antibiotics to various organisms, for example, Staphylococcus, Streptococcus, Enterococci, and Pseudomonas there is a renewed interest in the discovery of new antibacterials. Oxazolidinones, totally synthetic class of novel antibacterials, possess activity against drug-resistant Gram-positive pathogens, especially MRSA. Linezolid, the first approved drug from this class, has shown a great promise in saving lives of many patients by acting against drug-resistant Gram-positive organisms. However, its use is somewhat limited because of its myelotoxicity when used long term (>21 days). Various research groups are active in this area either to improve myelotoxicity profile of linezolid or to expand the spectrum of activity of linezolid. In spite of active research in this area, the discovery of an oxazolidinone possessing improved myelotoxicity compared to linezolid, linezolid-like efficacy, and PK remains challenging.

show abstract

Linezolid for the treatment of diabetic foot infections

Abstract: The hemostatic safety of strontium ranelate in the elderly population with osteoporosis was shown over 2 months of treatment; however, its long-term hemostatic safety should be evaluated further.

Cited by 2 publications

References 67 publications

Plasma Triglycerides as Predictors of Platelet Responsiveness to Aspirin in Patients after First Ischemic Stroke

Plasma Triglycerides as Predictors of Platelet Responsiveness to Aspirin in Patients after First Ischemic Stroke

New oxazolidinones

Contact Info

Product

Resources

About